托伐普坦治疗ADPKD患者尿量的决定因素
该临床试验纳入27例ADPKD患者,在基线、托伐普坦治疗3周后及洗脱3周后评估24小时尿量。结果显示V2RA治疗使尿量中位增加128%至5930±1790mL,24小时渗透质排泄与尿量强相关,而mGFR、总肾体积及药物浓度无独立关联,提示限制渗透质摄入或可减轻多尿。
要点
- V2RA治疗使ADPKD患者尿量中位增加128%,达5930±1790mL。
- 24小时渗透质排泄是V2RA使用期间尿量的主要决定因素。
- 限制渗透质摄入可能减轻V2RA所致多尿,改善耐受性。
核心结论
- 渗透质排泄是使用V2RA的ADPKD患者尿量的主要决定因素,限制渗透质摄入可能限制V2RA诱导的多尿。
研究设计与样本
- 临床试验,纳入27例ADPKD患者,在基线、V2RA治疗3周后及洗脱3周后评估。
主要发现
- V2RA治疗使尿量中位增加128%(IQR 75%-202%),至5930±1790mL。
- 24小时渗透质排泄与24小时尿量强相关(标准化β=0.73;P<0.001)。
- V2RA使用期间,24小时尿量与mGFR、总肾体积或V2RA浓度无独立关联。
临床怎么用
- 临床可考虑通过限制渗透质摄入来管理V2RA相关多尿,改善患者对药物的耐受性。
局限性
- 样本量有限,未采用标准化饮食。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RATIONALE & OBJECTIVE: The vasopressin V2 receptor antagonist (V2RA) tolvaptan is the first drug that has been shown to slow the rate of kidney function decline in patients with autosomal dominant polycystic kidney disease (ADPKD). However, V2RAs also cause polyuria, with urine output that averages 6L/d. We assessed determinants of urine volume in patients with ADPKD using V2RAs because such information may help develop strategies to improve V2RA tolerability. STUDY DESIGN: Clinical trial of patients with ADPKD studied at baseline, after 3 weeks of V2RA treatment (tolvaptan, 90/30mg, in the last week), and after a 3-week washout period. SETTING & PARTICIPANTS: The trial included patients with ADPKD with a wide range of kidney function (measured glomerular filtration rates [mGFRs]; range, 18-148mL/min/1.73m2). INTERVENTION: Tolvaptan treatment for 3 weeks. OUTCOMES: 24-hour urine volume. ANALYTICAL APPROACH: Multivariable regression analysis with stepwise backward elimination was performed both during and without V2RA treatment to evaluate the influence of 24-hour osmolar excretion, mGFR, and total kidney volume on associations between tolvaptan and urine volume. RESULTS: Included were 27 patients (48% men, aged 46±9.8 years with mGFRs of 61±35mL/min/1.73m2). V2RA treatment caused a median increase in urine volume of 128% (interquartile range, 75%-202%), to 5,930±1,790mL. 24-hour osmolar excretion was strongly associated with 24-hour urine volume (standardized β = 0.73; P < 0.001). During V2RA use, no independent associations were detected between 24-hour urine volume and mGFR, total kidney volume, or V2RA concentration. LIMITATIONS: Limited sample size, no standardized diets. CONCLUSIONS: Osmolar excretion is the major determinant of urine volume in patients taking V2RAs as a consequence of the inability to concentrate urine. Restriction of osmolar intake may therefore limit V2RA-induced polyuria, giving patients more control over the aquaretic side effects and improving the tolerability of these drugs.
引用
- Kramers BJ, van Gastel MDA, Boertien WE, et al. Determinants of Urine Volume in ADPKD Patients Using the Vasopressin V2 Receptor Antagonist Tolvaptan. Am J Kidney Dis. 2018. PMID: 30578153. doi:10.1053/j.ajkd.2018.09.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。